OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation Completion of Tedopi’s phase 3 in Non-Small Cell Lung Cancer One or two new rare/specialty ...

US President Donald Trump’s emissaries to the Kremlin may have been spinning their wheels during talks last week in Moscow on ...

Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...

Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a global leader in pharmaceutical manufacturing, and Corealis Pharma Inc ...

Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these ...

GERMANTOWN, MD AND HOUSTON, TX / ACCESS Newswire / December 9, 2025 / uBriGene Biosciences, a global CDMO specializing in Advanced Therapy Medicinal Product (ATMP) GMP development and manufacturing, ...

The Trump administration released its much-anticipated National Security Strategy this week. CFR convened six of its experts ...

Lifting the two-child benefit limit – at a cost of £3bn – will improve the life chances of more than half a million young ...

Biomind Labs Inc ( ($TSE:BMND) ) has issued an update. Biomind Labs Inc. has announced a significant strategic advancement in the development of ...

Viking Therapeutics advances oral and injectable VK2735 for obesity with strong cash, pipeline depth, and key 2026 catalysts.

AVIM Therapy for the Treatment of Hypertensive Heart Disease, presented by Avi Fischer, M.D., Senior Vice President of Medical Affairs and Innovation, Orchestra Biomed (December 8, 2025; 15:12 IST / ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...